

全宇生技控股有限公司
ALL COSMOS BIO-TECH HOLDING CORPORATION
2025 Annual General Meeting
Meeting Minutes

Date/Time: 16 June 2025, 9:00 a.m

Venue: 15F, No. 99, Fuxing N. Rd., Songshan Dist., Taipei City

Method: Physical meeting

Total number of shares represented and by proxy was 52,157,342 shares (including 11,240,341 shares exercised by electronic means), representing 81.45% of the total number of 64,034,001 shares issued.

Directors presented: Peng Shih-Hao, Peng Chia-Lin, Lim Tau Boon, Lo Tzu-Wu

Independent directors represented: Yang Yung-Cheng, Lee Wen-Chuan, Juan Chiung-Hua, Ho Chia-Fang

Attendees: CFO Janice Cheow, Deloitte CPA Yu Cheng-Chuan

Chairman: Peng Shih-Hao

Minutes recorder: Danys Liu

The number of representative shares of the shareholders present has reached the statutory number, and the chairman announced the start of the meeting.

1. Chairman's Remarks: (Omitted)

2. Report Items

Agenda 1: Year 2024 Business Report. (Refer to Attachment I)

Agenda 2: Audit Committee's Review Report for Year 2024 Financial Statements. (Refer to Attachment II)

Agenda 3: Report on the Distribution of Employees' Compensation and Directors Remuneration for Year 2024.

Explanatory Notes :

- (1) Pursuant to the Company's Articles of Incorporation and as approved by the Company's Board of Directors, it is hereby to declare NT\$4,060,781 as the Company's 2024 employees' compensation, and NT\$2,707,187 is declared as directors' remuneration, each of which represent 3.00% and 2.00% of profit before tax respectively.
- (2) There is no difference between the distribution of 2024 employees' compensation and directors' remuneration and the estimated amount of expenses on the account for the current year. Both are paid in cash.

Agenda 4: Report on Year 2024 Earnings Distribution Proposal

Explanatory Notes :

- (1) Pursuant to clause 125 A of the Company's Articles of Incorporation, to authorize the board of directors to make a special resolution to pay all or part of the dividends payable in cash and report in Shareholders Meeting.
- (2) 2024 net profit after tax is NT\$128,588,414 the proposed earnings distribution is NT\$32,017,000 in cash. Cash dividends on common shares will be distributed as NT\$0.50 each share.
- (3) Please refer to Attachment VI for Earnings Distribution Proposal.

Agenda 5: Execution Report on the First Unsecured Convertible Bond in Republic of China

Explanatory Notes :

The company’s board of directors resolved to issue 5,000 unit of the 3-year first unsecured convertible corporate bond in the Republic of China on September 21, 2022, as of the closing date (April 18, 2025), investors have not applied for exchanging corporate bonds, the Company has repaid NT\$459,300,000, and the outstanding amount is NT\$40,700,000.

Agenda 6: Report on amendments of “Procedure Rules of Director Meetings”

Explanatory Notes :

In response to the recent amendment to Taiwan’s Company’s Act, it is proposed to amend the Procedure Rules of Board of Director Meetings. Please refer to Attachment III for the comparison table of original and amended Rule.

Agenda 7: Report on amendments of “Corporate Governance Best Practice Principles”

Explanatory Notes :

In response to the recent amendment to Taiwan’s Company’s Act, it is proposed to amend the Corporate Governance Best Practice Principles. Please refer to Attachment IV for the comparison table of original and amended Rule.

3. Recognition Items

Agenda 1: Year 2024 Business Report and Financial Statements. (Proposed by the Board of Directors)

Explanatory Notes:

- (1) The Company’s Year 2024 Consolidated Financial Statements, have been duly audited by Independent Auditors, Yu Cheng Chuan and Liang Sheng Tai of Deloitte & Touche with unqualified opinions. In addition, Year 2024 Business Report and Consolidated Financial Statements have been duly approved by the Board of Directors and examined by the Audit Committee.
- (2) Please refer to Attachment I for the 2024 Business Report, and Attachment V for the Consolidated Financial Statements of this Handbook.

Resolved: Approved as proposed, voting results as follows:

Number of votes represented by attending shareholders: 52,157,342

Voting result	Accounted for the voting rights of the attending shareholders (%)
Votes in favor: 51,236,456 (Inclusive of electronic voting rights:11,173,455)	98.23%
Votes against:4,549 (Inclusive of electronic voting rights : 4,549)	0.00%
Invalid votes: 0 (Inclusive of electronic voting rights : 0)	0.00%
Abstaining votes and no votes: 916,337 (Inclusive of electronic voting rights : 62,337)	1.75%

Agenda 2: Year 2024 Earnings Distribution Proposal (Proposed by the Board of Directors)

Explanatory Notes:

Year 2024 Earnings Distribution Proposal was approved by the Board of Directors and reviewed by the Audit Committee. Please refer to Attachment VI for Earnings Distribution Statement.

Resolved: Approved as proposed, voting results as follows:

Number of votes represented by attending shareholders: 52,157,342

Voting result	Accounted for the voting rights of the attending shareholders (%)
Votes in favor: 51,213,456 (Inclusive of electronic voting rights: 11,150,455)	98.19%
Votes against: 27,549 (Inclusive of electronic voting rights:27,549)	0.05%
Invalid votes: 0 (Inclusive of electronic voting rights: 0)	0.00%
Abstaining votes and no votes: 916,337 (Inclusive of electronic voting rights : 62,337)	1.75%

4. Discussion Items

Agenda 1: The issuance of new shares from earnings of the company (Proposed by the Board of Directors)

Explanatory Notes:

- (1) The registered paid-in capital of the Company as of December 31, 2024 is NT\$640,340,010. In order to increase the capital scale and strengthen financial structure, the Company plans to increase capital by NT\$32,017,000 from earnings, issue 3,201,700 new shares with a par value of NT\$10 per share. The paid-in capital after the capital increase is NT\$672,357,010.
- (2) The original shareholders will be allotted 50 new shares for every thousand shares they hold as stated in the shareholder register on record date. In accordance with Article 240 of the Company Act, shareholders who are allotted fractional shares that are less than one share may go to the stock agency within 5 days from the final day of stock transfer to make up a whole share, all shares less than one share shall be purchased by the Chairman in consultation with a specific person at par value, calculated up to NTD (anything below NTD shall be rounded down). For shareholders who participate in the book-entry transfer allotment of shares, any fractional share amount that is less than one share will be used as the cost of handling the book-entry transfer.
- (3) The rights and obligations of the new shares issued in this capital increase are the same as those of the previously issued shares.
- (4) If the Company subsequently repurchases its own shares or transfers, converts, cancels shares, or otherwise increases or decreases shares, which affects the number of outstanding shares and causes a change in the shareholders' allotment ratio, the Shareholders' Meeting will decide whether to authorize the Chairman to handle the matter with full authority.
- (5) The ex-rights date is subject to approval by the shareholders' meeting. If there is any change due to the regulations of the competent authority or objective circumstances, the board of directors is authorized to determine it with full authority.

Resolved: Approved as proposed, voting results as follows:

Number of votes represented by attending shareholders: 52,157,342

Voting result	Accounted for the voting rights of the attending shareholders (%)
Votes in favor: 51,236,456 (Inclusive of electronic voting rights: 11,173,455)	98.23%
Votes against: 4,551 (Inclusive of electronic voting rights:4,551)	0.00%
Invalid votes: 0 (Inclusive of electronic voting rights: 0)	0.00%
Abstaining votes and no votes: 916,335 (Inclusive of electronic voting rights : 62,335)	1.75%

Agenda 2 : Amendments to the Company’s “Articles of Association” (Proposed by the Board of Directors)

Explanatory Notes:

Amendments are proposed in response to legal requirement and operational needs, please refer to Appendix VII for comparison table of the revised articles,

Resolved: Approved as proposed, voting results as follows:

Number of votes represented by attending shareholders: 52,157,342

Voting result	Accounted for the voting rights of the attending shareholders (%)
Votes in favor: 51,238,443 (Inclusive of electronic voting rights: 11,175,442)	98.23%
Votes against: 4,560 (Inclusive of electronic voting rights:4,560)	0.00%
Invalid votes: 0 (Inclusive of electronic voting rights: 0)	0.00%
Abstaining votes and no votes: 914,339 (Inclusive of electronic voting rights : 60,339)	1.75%

5. Election Items

Agenda 1: Proposal for re-election of directors (including independent directors) of the company (Proposed by the Board of Directors)

Explanatory Notes:

- (1) The term of office of the sixth term of directors of the Company will terminate on June 21, 2025. In this election, 9 directors (including 4 independent directors) will be elected according to the company’s articles of association. The new directors will take over after being elected at shareholders meeting this year, and the original directors will be dismissed at the same time for a term of three years from June 16, 2025 to June 15, 2028.
- (2) Please refer to Appendix VIII of this handbook for the list of candidates approved by the board of directors this year, as well as their studies and experience.
- (3) The current independent director candidate Yang Yung Cheng has served as the independent director of the company for more than three terms. Considering his professional knowledge in accounting and extensive auditing experience, familiarity with the company’s operating model, and upholding independent and objective standpoints to provide valuable advice and perform supervisory functions. Therefore, he will continue to be nominated as an independent director candidate.

Resolved: Approved as proposed, the list of directors elected (including independent directors) are as follows:

Type	Name	Shares
Director	Peng Shih Hao	106,208,144
Director	Peng Chia Lin	38,404,141
Director	Peng Yi Fen	38,397,644
Director	Lim Tau Boon	38,379,144
Director	Lo Tzu Wu	38,390,141
Independent Director	Yang Yung Cheng	38,391,041
Independent Director	Lee Wen Chuan	38,346,041
Independent Director	Juan Chiung Hua	38,386,541
Independent Director	Ho Chia Fang	38,391,131

6. Other Matters

Agenda 1 : Proposal of release the prohibition on directors from participation in competitive business (Proposed by the Board of Directors)

Explanatory Notes:

- (1) Pursuant to Section 209 of the Companies Act, directors should explain the important content of their actions and obtain permission for their own or others' actions within the scope of business of the company at shareholders' meeting.
- (2) Please refer to Appendix IX of this handbook for the content of the positions to be lifted from the non-compete restriction

Resolved: Approved as proposed, voting results as follows:

Number of votes represented by attending shareholders: 52,157,342

Voting result	Accounted for the voting rights of the attending shareholders (%)
Votes in favor: 51,256,407 (Inclusive of electronic voting rights: 11,193,406)	98.27%
Votes against:8,562 (Inclusive of electronic voting rights:8,562)	0.01%
Invalid votes: 0 (Inclusive of electronic voting rights: 0)	0.00%
Abstaining votes and no votes: 892,373 (Inclusive of electronic voting rights : 38,373)	1.71%

7. Extempore Motion

After inquiring all participating shareholders, no one raised ad hoc motions.

8. Summary of Questions and Responses

Shareholder No. 8895: Will the increasingly strict ESG requirements of the EU help boost fertilizer sales in the second half of the year?

Chairman's reply: ESG is helpful to the demand for compound fertilizers. If the price of chemical fertilizers rises and the price difference with compound fertilizers narrows, customers will have a greater incentive to use compound fertilizers. In addition, if chemical fertilizers can maintain high prices and low volatility at the same time, it will be even more beneficial to the sales of compound fertilizers. Overall, the company is optimistic about the demand in the second half of the year.

9. Meeting Adjourned

Chairman announced meeting adjourned at 9:44 a.m.

Chairman: Peng Shih Hao

Minutes recorded by: Danys Liu

Attachments

Attachment I

All Cosmos Bio-Tech Holding Corporation.

Business Report 2024

Palm oil prices have continued to rise since mid-2023 due to changes in the global palm oil supply and demand balance. Oil palm trees bloom and produce fruit all year round, producing yield is highly affected by temperature, rainfall, and fertilization. However, between April 2023 and March 2024, the El Niño climate caused high temperatures and drought in major oil palm producing areas in Southeast Asia, such as Indonesia and Malaysia. Together with the climate impact caused by La Niña after June 2024, global oil palm production will decline in 2024. As demand remains strong, the price of palm oil is expected to increase by 9.7% from an average of MYR3,809.50 per tonne in 2023 to MYR4,179.50 per tonne in 2024.

As the pioneer of bio-chemical fertilizer in Malaysia, fertilizers provided by the company not only significantly help with fruit yield, but also have a positive impact on soil conservation and improvement. The company's long-term business operations in microbes, health food, and plant vaccines are gradually bringing in good results, and continue to strengthen its role in palm oil industry, the cumulative revenue for 2024 is NT\$2,458,636 thousand.

1. 2024 Operation Results

1.1 Business plan implementation results

Unit: NT\$ in Thousand ; %

	2024	2023	Increase(Decrease) Amount	Change Ratio
Operating Revenue	2,458,636	2,826,587	(367,951)	(13.02%)
Gross Profit	668,591	587,979	80,612	13.71%
Net Profit For The Year	128,588	139,361	(10,773)	(7.73%)

The company's fertilizer sales structure is mainly based on large plantation bids, supplemented by small farmers. The sales price of the bids is set on schedule, and the purchase price of small farmers fluctuates irregularly with market prices, both are positively correlated with the changes in raw material prices. The company has always maintained friendly relations with its customers and stable sales and shipments. 2024 revenue decreased by 13.02% in comparison with 2023 mainly because of the impact of the decreasing average selling price. Taking into account the impact of the overall environment and price adjustments, the company's profit in 2024 was NT\$128,599 thousand.

1.2 Financial Revenue and Profitability

Financial Ratio Item		2024	2023
Financial Structure (%)	Debt to Asset Ratio	14.72	23.40
	Long-Term Capital to Fixed Assets Ratio	331.25	362.41
Solvency (%)	Current Ratio	555.87	356.65
	Quick Ratio	391.91	267.19
Profitability (%)	Return on Assets	3.63	3.66
	Return on Equity	5.39	6.03
	Earning Per Share (NTD\$)	2.01	2.18

1.3 Development Strategy

The company will continue to be committed to the development of green agriculture and assist the upgrading and transformation of Malaysian agriculture. Also, the construction of the Indonesia factory was completed in 2024, and expects to expand the high growth potential Indonesian market with resource technology.

At the same time, it also further develops and sells health care products and uses technology to convert oil palm waste into functional sugar. This not only turns agricultural waste from waste into gold, but also takes into account health and environmental protection to achieve a circular economy.

1.4 Impacts of competition, regulation and overall economic environment

The company keeps up with the pulse of the industry and makes long-term plans for product development, customer relations and marketing management to enhance competitiveness and reduce the impact of the external competitive environment, and always pay attention to important domestic and foreign policies and legal changes. There were no changes in policies or laws that significantly affected the company's financial operations in recent years. Overall, the company is committed to the business fields it has been cultivating for a long time, continues to pursue quality improvement and expansion of applications, and carefully diversifies its business layout to reduce the impact of changes in the competitive environment, regulatory environment and the overall operating environment.

2. 2025 Operation Plan Summary:

The average CPO price will maintain at MYR4000-4300 per metric ton, according to the estimation of Malaysian Palm Oil Board (MPOB), higher than 2024 average price. Indonesia's B40 policy, which raises the percentage of palm oil in biodiesel blends from 35% to 40%, will reduce Indonesia's palm oil exports and increase the chances that other countries will shift their purchasing demand to Malaysia. Also, the importance of ESG led plantations paying more attention to the increased fruit yield and environmental benefits brought by biochemical organic compound fertilizers. Driven by multi-faceted benefits, the company will be able to further strengthen its connections with customers in 2025 through field experiments, education, cooperation, charity and product sales. As for other products, the health food business will also maintain steady growth and expand sales areas through more diversified products and sales methods.

The company has 20 years deep cultivation in the Malaysian biochemical fertilizer market, has more than 600 kinds of microbial strains and is the pioneer in the global bio-compound fertilizer industry. As global awareness on sustainable agriculture, improvement of soil degradation and ecological problems arise, the company's advanced technology can help to improve and maintain the environment moving towards the goal of green agriculture. Through continuous efforts to improve, research and development, we lay a solid foundation for future growth.

We hope that we can show our business results to our shareholders with our peers' efforts and our dedication. We commit to the spirit of continuous improvement and would like to thank our partners, shareholders and hardworking staffs for your long-standing support. Thank you for allowing me to express my sincere gratitude here!

All Cosmos Bio-Tech Holding Corporation
Chairman Peng Shih Hao

Attachment II

All Cosmos Bio-Tech Holding Corporation

Review Report of the Audit Committee

The Board of Directors has prepared this Company's 2024 business report, financial statements (including consolidated financial statements) and the earnings distribution plan, among which the financial statements (including consolidated financial statement) have been audited by Independent Auditors, Mr. Yu Cheng Chuan and Mr. Liang Sheng Tai of Deloitte & Touche, who have submitted an audit report. The above statements and reports have been examined by the Audit Committee and no irregularities were found. We hereby report as above in accordance with the Securities and Exchange Act. Please kindly approve.

2025 Annual General Meeting of
All Cosmos Bio-Tech Holding Corporation

Audit Committee Convener
Yang Yung Cheng

Date : March 13, 2025

Attachment III

Comparison table of Original and Amended “Regulations Governing Procedure for Board of Directors Meetings”

Article Number	Current Articles	Amended Articles	Explanations
Article 7	<p>(Board of Directors Reference Materials, Attendees and Board Meetings)</p> <p>When the board of directors of ACBT is convened, the management department (or the designated deliberation unit of the board of directors) should prepare relevant data for the attending directors to check at any time.</p> <p>When convening a board meeting, personnel from relevant departments or subsidiaries may be notified to attend as observers based on the content of the proposal. When necessary, accountants, lawyers, or other professionals may also be invited to attend the meeting and provide explanations. But when discussing and voting, one should leave the seat.</p> <p>The chairman of the board of directors shall announce the meeting immediately when more than half of the directors are present at the current meeting time.</p> <p>At the current meeting time, if half of the directors are not present, the chairman may announce a postponement of the meeting, with a maximum of two postponements. If the postponement is still insufficient, the chairman may convene a new meeting in accordance with the procedures stipulated in Article 3, Paragraph 2. The term "all directors" referred to in the preceding paragraph and Article 15, Paragraph 2, Item 2 shall be calculated based on those who are actually in office.</p>	<p>(Board of Directors Reference Materials, Attendees and Board Meetings)</p> <p>When the board of directors of ACBT is convened, the management department (or the designated deliberation unit of the board of directors) should prepare relevant data for the attending directors to check at any time.</p> <p>When convening a board meeting, personnel from relevant departments or subsidiaries may be notified to attend as observers based on the content of the proposal. When necessary, accountants, lawyers, or other professionals may also be invited to attend the meeting and provide explanations. But when discussing and voting, one should leave the seat.</p> <p>The chairman of the board of directors shall announce the meeting immediately when more than half of the directors are present at the current meeting time.</p> <p>At the current meeting time, if half of the directors are not present <u>at the meeting time</u>, the chairman may announce a postponement of the meeting, with a maximum of two postponements. If the postponement is still insufficient, the chairman may convene a new meeting in accordance with the procedures stipulated in Article 3, Paragraph 2. The term "all directors" referred to in the preceding paragraph and Article 15, Paragraph 2, Item 2 shall be calculated based on those who are actually in office.</p>	<p>Wording revisions made in accordance with the revision of laws and regulations.</p>

Article Number	Current Articles	Amended Articles	Explanations
Article 10	<p>(Proposal for Discussion)</p> <p>The board of directors of ACBT shall conduct its proceedings in accordance with the procedures set out in the meeting notice. But with the consent of more than half of the attending directors, it may be changed.</p> <p>The chairman shall not announce the adjournment of the meeting without the consent of more than half of the attending directors.</p> <p>During the proceedings of the board of directors meeting, if the number of directors present is less than half of the total number of directors present, the chairman shall, upon the proposal of the directors present, announce the suspension of the meeting and apply the provisions of Article 7, Paragraph 4.</p>	<p>(Proposal for Discussion)</p> <p>The board of directors of ACBT shall conduct its proceedings in accordance with the procedures set out in the meeting notice. But with the consent of more than half of the attending directors, it may be changed.</p> <p>The chairman shall not announce the adjournment of the meeting without the consent of more than half of the attending directors.</p> <p>During the proceedings of the board of directors meeting, if the number of directors present is less than half of the total number of directors present, the chairman shall, upon the proposal of the directors present, announce the suspension of the meeting and apply the provisions of Article 7, Paragraph 4.</p> <p><u>During the proceedings of the board of directors meeting, if the chairman is unable to preside over the meeting or fails to declare the meeting to adjourn in accordance with the provisions of Paragraph 2, the provision of Paragraph 3 of Article 6 shall apply mutatis mutandis to the selection and appointment of his proxy.</u></p>	<p>Wording revisions made in accordance with the revision of laws and regulations.</p>

Attachment IV

Comparison Table of Original and Amended “Corporate Governance Best Practice Principles”

Article Number	Current Articles	Amended Articles	Explanations
Article 3	<p>ACBT shall follow the Criteria Governing Establishment of Internal Control Systems by Public Reporting Companies and take into consideration the overall operational activities of itself and its subsidiaries to design and fully implement an internal control system, and shall conduct continuing reviews of the system, in order to ensure the continued effectiveness of its design and implementation in light of changes in the company's internal and external environment.</p> <p>ACBT shall perform full self-assessments of its internal control system. Its board of directors and management shall review the results of the self-assessments by each department at least annually and the reports of the internal audit department on a quarterly basis. The audit committee or supervisors shall also attend to and supervise these matters. Directors and supervisors shall periodically hold discussions with their internal auditors about reviews of internal control system deficiencies. A record of the discussions shall be kept, and the discussions shall be followed up, improvements implemented, and a report submitted to the board of directors.</p> <p>ACBT has established channels and mechanisms of communication between their independent directors, audit committees or supervisors, and chief internal auditors, and the convener of the audit committee or</p>	<p>ACBT shall follow the Criteria Governing Establishment of Internal Control Systems by Public Reporting Companies and take into consideration the overall operational activities of itself and its subsidiaries to design and fully implement an internal control system, and shall conduct continuing reviews of the system, in order to ensure the continued effectiveness of its design and implementation in light of changes in the company's internal and external environment.</p> <p>ACBT shall perform full self-assessments of its internal control system. Its board of directors and management shall review the results of the self-assessments by each department at least annually and the reports of the internal audit department on a quarterly basis. The audit committee or supervisors shall also attend to and supervise these matters. Directors and supervisors shall periodically hold discussions with their internal auditors about reviews of internal control system deficiencies. A record of the discussions shall be kept, and the discussions shall be followed up, improvements implemented, and a report submitted to the board of directors.</p> <p>ACBT has established channels and mechanisms of communication between their independent directors, audit committees or supervisors, and chief internal auditors, and the convener of the audit committee or</p>	Wording revisions made in accordance with the revision of laws and regulations.

Article Number	Current Articles	Amended Articles	Explanations
Article 3	<p>supervisors shall report their communication with the independent directors and chief internal auditors at the shareholders' meeting.</p> <p>(Omitted Below)</p>	<p>supervisors shall report their communication with the <u>Audit Committee members or supervisor</u>, and chief internal auditors at the shareholders' meeting.</p> <p>(Omitted Below)</p>	
Article 3-1	<p>(Personnel responsible for corporate governance affairs)</p> <p>A TWSE/TPEX listed company is advised to have an adequate number of corporate governance personnel with appropriate qualifications based on the size of the company, business situations and management needs, and to appoint a chief corporate governance officer as the most senior officer to be in charge of corporate governance affairs. Said officer shall be a qualified, practice-eligible lawyer or accountant or have been in a managerial position for at least three years in a securities, financial, or futures related institution or a public company in handling legal affairs, financial affairs, stock affairs, or corporate governance affairs.</p> <p>It is required that the corporate governance affairs mentioned in the preceding paragraph include at least the following items:</p> <ol style="list-style-type: none"> 1. Handling matters relating to board meetings and shareholders meetings according to laws 2. Producing minutes of board meetings and shareholders meetings 3. Assisting in onboarding and continuous development of directors and supervisors 4. Furnishing information required for business execution by directors and supervisors 	<p>(Personnel responsible for corporate governance affairs)</p> <p>A TWSE/TPEX listed company is advised to have an adequate number of corporate governance personnel with appropriate qualifications based on the size of the company, business situations and management needs, and to appoint a chief corporate governance officer <u>in accordance with regulations of the competent authority, TWSE or TPEX</u> as the most senior officer to be in charge of corporate governance affairs. Said officer shall be a qualified, practice-eligible lawyer or accountant or have been in a managerial position for at least three years in <u>legal affairs, legal compliance affairs, internal audit affairs</u>, financial affairs, stock affairs, or corporate governance affairs.</p> <p>It is required that the corporate governance affairs mentioned in the preceding paragraph include at least the following items:</p> <ol style="list-style-type: none"> 1. Handling matters relating to board meetings and shareholders meetings according to laws 2. Producing minutes of board meetings and shareholders meetings 3. Assisting in onboarding and continuous development of directors and supervisors 4. Furnishing information required for business execution by directors and supervisors 	<p>Wording revisions made in accordance with the revision of laws and regulations.</p>

Article Number	Current Articles	Amended Articles	Explanations
Article 3-1	<p>5. Assisting directors and supervisors with legal compliance</p> <p>6. Other matters set out in the articles or corporation or contracts</p>	<p>5. Assisting directors and supervisors with legal compliance</p> <p>6. <u>Report to the Board on the results of its review of whether the qualifications of independent directors comply with relevant laws and regulations at the time of nomination, election and during their term of office.</u></p> <p>7. <u>Handle matters related to the change of directors.</u></p> <p>8. Other matters set out in the articles or corporation or contracts</p>	
Article 6	<p>The board of directors of ACBT shall properly arrange the agenda items and procedures for shareholders meetings, and formulate the principles and procedures for shareholder nominations of directors and supervisors and submissions of shareholder proposals. The board shall also properly handle the proposals duly submitted by shareholders. Arrangements shall be made to hold shareholders meetings at a convenient location, with sufficient time allowed and sufficient numbers of suitable personnel assigned to handle attendance registrations. No arbitrary requirements shall be imposed on shareholders to provide additional evidentiary documents beyond those showing eligibility to attend. Shareholders shall be granted reasonable time to deliberate each proposal and an appropriate opportunity to make statements.</p> <p>(Omitted below)</p>	<p>The board of directors of ACBT shall properly arrange the agenda items and procedures for shareholders meetings, and formulate the principles and procedures for shareholder nominations of directors and supervisors and submissions of shareholder proposals. The board shall also properly handle the proposals duly submitted by shareholders. Arrangements shall be made to hold shareholders meetings at a convenient location <u>and supplement by video conferencing,</u> with sufficient time allowed and sufficient numbers of suitable personnel assigned to handle attendance registrations. No arbitrary requirements shall be imposed on shareholders to provide additional evidentiary documents beyond those showing eligibility to attend. Shareholders shall be granted reasonable time to deliberate each proposal and an appropriate opportunity to make statements.</p> <p>(Omitted below)</p>	<p>Wording revisions made in accordance with the revision of laws and regulations.</p>
Article 7	<p>ACBT shall encourage its shareholders to actively participate in corporate governance. The</p>	<p>ACBT shall encourage its shareholders to actively participate in corporate governance. The company</p>	<p>Wording revisions made in accordance with</p>

Article Number	Current Articles	Amended Articles	Explanations
Article 7	<p>company has engaged a professional shareholder services agent to handle shareholders meeting matters, so that shareholders meetings can proceed on a legal, effective and secure basis. The company shall seek all ways and means, including fully exploiting technologies for information disclosure, to upload annual reports, annual financial statements, notices, agendas and supplementary information of shareholders meetings in both Chinese and English concurrently, and shall adopt electronic voting, in order to enhance shareholders' attendance rates at shareholders meetings and ensure their exercise of rights at such meetings in accordance with laws and is advised to avoid raising extraordinary motions and amendments to original proposals at a shareholders meeting, and is advised to adopt a candidate nomination system for the election of directors and supervisors.</p> <p>(Omitted Below)</p>	<p>has engaged a professional shareholder services agent to handle shareholders meeting matters, so that shareholders meetings can proceed on a legal, effective and secure basis. The company shall seek all ways and means, including fully exploiting technologies for information disclosure, to upload annual reports, annual financial statements, notices, agendas and supplementary information of shareholders meetings in both Chinese and English concurrently, and shall adopt electronic voting, in order to enhance shareholders' attendance rates at shareholders meetings and ensure their exercise of rights at such meetings in accordance with laws and is advised to avoid raising extraordinary motions and amendments to original proposals at a shareholders meeting, and is advised to adopt a candidate nomination system for the election of directors and supervisors.</p> <p>(Omitted Below)</p>	the revision of laws and regulations.
Article 10	<p>ACBT shall place high importance on the shareholder right to know, and shall faithfully comply with applicable regulations regarding information disclosure in order to provide shareholders with regular and timely information on company financial conditions and operations, insider shareholdings, and corporate governance status through the MOPS or the website established by the company.</p> <p>To treat all shareholders equally, it is advisable that the company concurrently disclose the information under the preceding paragraph in English.</p>	<p>ACBT shall place high importance on the shareholder right to know, and shall faithfully comply with applicable regulations regarding information disclosure in order to provide shareholders with regular and timely information on company financial conditions and operations, insider shareholdings, and corporate governance status through the MOPS or the website established by the company.</p> <p>To treat all shareholders equally, it is advisable that the company concurrently disclose the information under the preceding paragraph in English.</p>	Wording revisions made in accordance with the revision of laws and regulations.

Article Number	Current Articles	Amended Articles	Explanations
Article 10	To protect its shareholders' rights and interests and ensure their equal treatment, the company shall adopt internal rules prohibiting company insiders from trading securities using information not disclosed to the market.	To protect its shareholders' rights and interests and ensure their equal treatment, the company shall adopt internal rules prohibiting company insiders from trading securities using information not disclosed to the market. <u>The preceding specification should include the stock trading control measures of ACBT's insiders from the date of learning of the Company's financial reports or relevant results. Including (but not limited to) directors are not allowed to trade their shares during the closed period, namely 30 days before the announcement of the annual financial report and 15 days before the announcement of the quarterly financial report.</u>	
Article 17	When ACBT and its affiliated enterprises enter into inter-company business transactions, a written agreement governing the relevant financial and business operations between them shall be made in accordance with the principle of fair dealing and reasonableness. Price and payment terms shall be definitively stipulated when contracts are signed, and non-arm's length transactions shall be prohibited. All transactions or contracts made by and between ACBT and its affiliated persons and shareholders shall follow the principles set forth in the preceding paragraph, and improper channelling of profits is strictly prohibited.	When ACBT and its <u>relevant party and shareholder</u> enter into <u>finance and/or business dealings</u> and transactions, a written agreement governing the relevant financial and business operations between them shall be made in accordance with the principle of fair dealing and reasonableness. Price and payment terms shall be definitively stipulated when contracts are signed, and non-arm's length transactions <u>and improper transfer of benefits</u> shall be prohibited. All transactions or contracts made by and between ACBT and its affiliated persons and shareholders shall follow the principles set forth in the preceding paragraph, and improper channelling of profits is strictly prohibited. <u>The content of the written regulations in the preceding paragraph shall include the management procedures</u>	Wording revisions made in accordance with the revision of laws and regulations.

Article Number	Current Articles	Amended Articles	Explanations
Article 17		<u>for transactions such as purchase and sale of goods, acquisition or disposal of assets, loaning of funds and making of endorsement and guarantee, and relevant major transactions should be approved by the board of directors, approved or reported by the shareholders' meeting.</u>	
Article 20	<p>(Omitted paragraph 1 to 2)</p> <p>The composition of the board of directors shall be determined by taking diversity into consideration. It is advisable that directors concurrently serving as company officers not exceed one-third of the total number of the board members, and that an appropriate policy on diversity based on the company's business operations, operating dynamics, and development needs be formulated and include, without being limited to, the following two general standards:</p> <ol style="list-style-type: none"> 1. Basic requirements and values: Gender, age, nationality, and culture. 2. Professional knowledge and skills: A professional background (e.g., law, accounting, industry, finance, marketing, technology), professional skills, and industry experience. <p>(Omitted paragraph 4)</p>	<p>(Omitted paragraph 1 to 2)</p> <p>The composition of the board of directors shall be determined by taking diversity into consideration. It is advisable that directors concurrently serving as company officers not exceed one-third of the total number of the board members, and that an appropriate policy on diversity based on the company's business operations, operating dynamics, and development needs be formulated and include, without being limited to, the following two general standards:</p> <ol style="list-style-type: none"> 1. Basic requirements and values: Gender, age, nationality, and culture. <u>The ratio of female directors should reach one-third of the director seats.</u> 2. Professional knowledge and skills: A professional background (e.g., law, accounting, industry, finance, marketing, technology), professional skills, and industry experience. <p>(Omitted paragraph 4)</p>	Wording revisions made in accordance with the revision of laws and regulations.
Article 22	ACBT has specify in its articles of incorporation that it adopts the candidate nomination system for elections of directors, carefully review the qualifications of a nominated candidate and the existence of any other matters set	<u>ACBT shall comply with the regulations of the competent authority to specify in its articles of incorporation that election of directors shall adopt</u> candidate nomination system, carefully review the qualifications of a nominated	Wording revisions made in accordance with the revision of laws and regulations.

Article Number	Current Articles	Amended Articles	Explanations
	forth in Article 30 of the Company Act, and act in accordance with Article 192-1 of the Company Act.	candidate and the existence of any other matters set forth in Article 30 of the Company Act, and act in accordance with Article 192-1 of the Company Act.	
Article 24	ACBT shall appoint independent directors in accordance with its articles of incorporation. They shall be not less than two in number and not less than one-fifth of the total number of directors. (Omitted paragraph 2 to 6)	ACBT shall appoint independent directors in accordance with its articles of incorporation. They shall be not less than two in number and not less than one-third of the total number of directors, the consecutive term of independent directors should not exceed three terms. (Omitted paragraph 2 to 6)	Wording revisions made in accordance with the revision of laws and regulations.
Article 28	ACBT shall establish either an audit committee or a supervisor. (Omitted below)	ACBT shall establish either an audit committee or a supervisor . (Omitted below)	Wording revisions made in accordance with the revision of laws and regulations.
Article 29	(Omitted paragraph 1 to 4) ACBT has evaluated the independence and suitability of the CPA engaged by the company regularly, and no less frequently than once annually. In the event that the company engages the same CPA without replacement for 7 years consecutively, or if the CPA is subject to disciplinary action or other circumstances prejudicial to the CPA's independence, the company shall evaluate the necessity of replacing the CPA and submit its conclusion to the board of directors.	(Omitted paragraph 1 to 4) ACBT <u>shall reference to standards of AQIs to</u> evaluate the independence and suitability of the CPA engaged by the company regularly, and no less frequently than once annually. In the event that the company engages the same CPA without replacement for 7 years consecutively, or if the CPA is subject to disciplinary action or other circumstances prejudicial to the CPA's independence, the company shall evaluate the necessity of replacing the CPA and submit its conclusion to the board of directors.	Wording revisions made in accordance with the revision of laws and regulations.
Article 37	Members of the board of directors shall faithfully conduct corporate affairs and perform the duty of care of a good administrator. In conducting the affairs of the company, they shall exercise their powers with a high level of self-discipline and prudence. Unless	Members of the board of directors shall faithfully conduct corporate affairs and perform the duty of care of a good administrator. In conducting the affairs of the company, they shall exercise their powers with a high level of self-discipline and prudence. Unless	Wording revisions made in accordance with the revision of laws and regulations.

Article Number	Current Articles	Amended Articles	Explanations
Article 37	<p>matters are otherwise reserved by law for approval in shareholders meetings or in the articles of incorporation, they shall ensure that all matters are handled according to the resolutions of board of directors.</p> <p>ACBT formulate rules and procedures for board of directors performance assessments, and that each year it conducts regularly scheduled performance assessments of the board of directors, functional committees, and individual directors through self-assessment, peer-to-peer assessments, engaging outside professional institutions, or in any other appropriate manner. It is advisable that the performance assessment of the board of directors include the following aspects, and that appropriate assessment indicators be developed in consideration of the company's needs:</p> <ol style="list-style-type: none"> 1. The degree of participation in the company's operations. 2. Improvement in the quality of decision making by the board of directors. 3. The composition and structure of the board of directors. 4. The election of the directors and their continuing professional education. 5. Internal controls. <p>It is advisable that performance assessments of board members (self-assessments or peer-to-peer assessments) include the following aspects, with appropriate adjustments made on the basis of the company's needs:</p> <ol style="list-style-type: none"> 1. Their grasp of the company's goals 	<p>matters are otherwise reserved by law for approval in shareholders meetings or in the articles of incorporation, they shall ensure that all matters are handled according to the resolutions of board of directors.</p> <p>ACBT <u>shall</u> formulate rules and procedures for board of directors' performance assessments, <u>except</u> that each year it conducts regularly scheduled performance assessments of the board of directors, functional committees, individual directors through self-assessment, <u>or</u> peer-to-peer assessments, <u>could also</u> engage outside professional institutions, or in any other appropriate manner. It is advisable that the performance assessment of the board of directors <u>should</u> include the following aspects, and that appropriate assessment indicators be developed in consideration of the company's needs:</p> <ol style="list-style-type: none"> 1. The degree of participation in the company's operations. 2. Improvement in the quality of decision making by the board of directors. 3. The composition and structure of the board of directors. 4. The election of the directors and their continuing professional education. 5. Internal controls. <p>It is advisable that performance assessments of board members (self-assessments or peer-to-peer assessments) <u>should</u> include the following aspects, with appropriate adjustments made on the basis of the company's needs:</p> <ol style="list-style-type: none"> 1. Their grasp of the company's goals 	

Article Number	Current Articles	Amended Articles	Explanations
Article 37	<p>and missions.</p> <ol style="list-style-type: none"> 2. Their recognition of director's duties. 3. Their degree of participation in the company's operations. 4. Their management of internal relationships and communication. 5. Their professionalism and continuing professional education. 6. Internal controls. <p>It is advisable that the performance assessment of a functional committee cover the following aspects, subject to changes according to the company's needs:</p> <ol style="list-style-type: none"> 1. Their degree of participation in the company's operations. 2. Their recognition of the duties of the functional committee. 3. Improvement in the quality of decision making by the functional committee. 4. The composition of the functional committee, and election and appointment of committee members. 5. Internal control. <p>ACBT submits the results of performance assessments to the board of directors and use them as reference in determining compensation for individual directors, their nomination and additional office term.</p>	<p>and missions.</p> <ol style="list-style-type: none"> 2. Their recognition of director's duties. 3. Their degree of participation in the company's operations. 4. Their management of internal relationships and communication. 5. Their professionalism and continuing professional education. 6. Internal controls. <p>It is advisable that the performance assessment of a functional committee cover the following aspects, subject to changes according to the company's needs:</p> <ol style="list-style-type: none"> 1. Their degree of participation in the company's operations. 2. Their recognition of the duties of the functional committee. 3. Improvement in the quality of decision making by the functional committee. 4. The composition of the functional committee, and election and appointment of committee members. 5. Internal control. <p>ACBT submits the results of performance assessments to the board of directors and use them as reference in determining compensation for individual directors, their nomination and additional office term.</p>	
Article 40	<p>Members of the board of directors are advised to participate in training courses on finance, risk management, business, commerce, accounting, law or corporate social responsibility offered by institutions designated in the Rules Governing</p>	<p>Members of the board of directors are advised to participate in training courses on finance, risk management, business, commerce, accounting, law or corporate social responsibility offered by institutions designated in the Rules Governing</p>	<p>Wording revisions made in accordance with the revision of laws and regulations.</p>

Article Number	Current Articles	Amended Articles	Explanations
Article 40	Implementation of Continuing Education for Directors and Supervisors of ACBTs, which cover subjects relating to corporate governance upon becoming directors and throughout their terms of occupancy. They shall also ensure that company employees at all levels will enhance their professionalism and knowledge of the law.	Implementation of Continuing Education for Directors and Supervisors of ACBTs, which cover subjects relating to corporate governance upon becoming directors and throughout their terms of occupancy. They shall also ensure that company employees at all levels will enhance their professionalism and knowledge of the law.	
Article 42	ACBT has specify in its articles of incorporation that it adopts the candidate nomination system for elections of supervisors, carefully review the qualifications of a nominated candidate and the existence of any other matters set forth in Article 30 of the Company Act, and act in accordance with Article 192-1 of the Company Act.	ACBT <u>shall</u> specify in its articles of incorporation that elections of supervisors <u>should adopt nomination system</u> , carefully review the qualifications of a nominated candidate and the existence of any other matters set forth in Article 30 of the Company Act, and act in accordance with Article 192-1 of the Company Act <u>to comply with regulations of competent authority</u> .	Wording revisions made in accordance with the revision of laws and regulations.
Article 50	Upon becoming supervisors and throughout their terms, supervisors are advised to participate in training courses on finance, risk management, business, commerce, accounting, law or corporate social responsibility offered by institutions designated in the Rules Governing Implementation of Continuing Education for Directors and Supervisors of ACBT covering subjects relating to corporate governance.	Upon becoming <u>board members</u> and throughout their terms, supervisors are advised to participate in training courses on finance, risk management, business, commerce, accounting, law or corporate social responsibility offered by institutions designated in the Rules Governing Implementation of Continuing Education for Directors and Supervisors of ACBT covering subjects relating to corporate governance. <u>Employees at all levels are also tasked to enhance their professional and legal knowledge</u> .	Wording revisions made in accordance with the revision of laws and regulations.

Attachment V

**All Cosmos Bio-Tech Holding Corporation and
Subsidiaries**

**Consolidated Financial Statements for the
Years Ended December 31, 2024 and 2023 and
Independent Auditors' Report**

Address: One Nexus Way Camana Bay, Grand
Cayman, KY1-9005 Cayman Islands

Telephone: (607)252-3788

INDEPENDENT AUDITORS' REPORT

The Board of Directors and Shareholders
All Cosmos Bio-Tech Holding Corporation

Opinion

We have audited the accompanying consolidated financial statements of All Cosmos Bio-Tech Holding Corporation (the “Company”) and its subsidiaries (collectively referred to as the “Group”), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including material accounting policy information (collectively referred to as the “consolidated financial statements”).

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2024 and 2023, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and International Financial Reporting Standards (IFRS), International Accounting Standards (IAS), IFRIC Interpretations (IFRIC), and SIC Interpretations (SIC) endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Financial Statement Audit and Attestation Engagements of Certified Public Accountants and the Standards on Auditing of the Republic of China. Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with The Norm of Professional Ethics for Certified Public Accountant of the Republic of China, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements for the year ended December 31, 2024. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matters identified in the Group's consolidated financial statements for the year ended December 31, 2024 are stated as follows:

Occurrence of Sales Revenue from Major Customers

The Group primarily focuses on the sale of bioorganic and biochemical compound fertilizers. Considering the higher inherent risk in revenue recognition and its significant impact on the Group's financial statements for major customers whose transaction amounts have significantly increased compared to the same period last year, we identified the occurrence of sales revenue from the aforementioned major customers as the key audit matter.

Refer to Notes 4 (n) and 24 to the consolidated financial statements for details on the accounting policy and relevant disclosures on revenue recognition.

The main audit procedures that we performed in respect of sales revenue from major customers included the following:

1. We obtained an understanding of the Group's internal control and operating procedures of the sales cycle, and we designed the corresponding audit procedures and tested the effectiveness of the internal controls associated with the risk mentioned above.
2. We performed substantive tests on sales revenue, selected samples from the general ledger of sales revenue, and checked the records against external supporting documents and documents of receivables to verify the occurrence of sales.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers, and IFRS, IAS, IFRIC, and SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance, including the audit committee, are responsible for overseeing the Group's financial reporting process.

Auditors' Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Standards on Auditing of the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with the Standards on Auditing of the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group to cease to continue as a going concern.
5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
6. Obtain sufficient and appropriate audit evidence regarding the financial information of entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision, and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements for the year ended December 31, 2024 and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audits resulting in this independent auditors' report are Cheng-Chuan Yu and Sheng-Tai Liang.

Deloitte & Touche
Taipei, Taiwan
Republic of China

March 13, 2025

Notice to Readers

The accompanying consolidated financial statements are intended only to present the consolidated financial position, financial performance and cash flows in accordance with accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally applied in the Republic of China.

For the convenience of readers, the independent auditors' report and the accompanying consolidated financial statements have been translated into English from the original Chinese version prepared and used in the Republic of China. If there is any conflict between the English version and the original Chinese version or any difference in the interpretation of the two versions, the Chinese-language independent auditors' report and consolidated financial statements shall prevail.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

	2024		2023	
	Amount	%	Amount	%
ASSETS				
CURRENT ASSETS				
Cash and cash equivalents (Notes 4 and 6)	\$ 933,928	26	\$ 1,458,863	40
Financial assets at fair value through profit or loss - current (Notes 4 and 7)	46,316	1	41,071	1
Financial assets at amortized cost - current (Notes 4, 9 and 34)	269,436	7	157,095	4
Trade receivables, net (Notes 4, 10 and 24)	587,783	16	406,014	11
Trade receivables from related parties (Notes 4, 24 and 33)	30,940	1	37,595	1
Other receivables (Notes 4 and 10)	4,270	-	3,706	-
Other receivables from related parties (Notes 4 and 33)	82	-	6,698	-
Current tax assets (Notes 4 and 26)	40,147	1	50,667	2
Inventories (Notes 4 and 11)	675,032	18	591,062	16
Prepayments (Note 18)	69,780	2	65,212	2
Other current assets (Note 18)	<u>3,526</u>	<u>-</u>	<u>395</u>	<u>-</u>
Total current assets	<u>2,661,240</u>	<u>72</u>	<u>2,818,378</u>	<u>77</u>
NON-CURRENT ASSETS				
Financial assets at fair value through other comprehensive income - non-current (Notes 4 and 8)	5,326	-	-	-
Investments accounted for using the equity method (Notes 4 and 13)	27,376	1	22,343	1
Property, plant and equipment (Notes 4, 14, 33 and 34)	777,899	21	641,159	17
Right-of-use assets (Notes 4, 15 and 34)	159,986	5	154,162	4
Goodwill (Notes 4 and 16)	383	-	1,108	-
Other intangible assets (Notes 4 and 17)	11,158	-	9,072	-
Deferred tax assets (Notes 4 and 26)	17,775	1	10,737	-
Other non-current assets (Note 18)	<u>9,431</u>	<u>-</u>	<u>16,776</u>	<u>1</u>
Total non-current assets	<u>1,009,334</u>	<u>28</u>	<u>855,357</u>	<u>23</u>
TOTAL	<u>\$ 3,670,574</u>	<u>100</u>	<u>\$ 3,673,735</u>	<u>100</u>
LIABILITIES AND EQUITY				
CURRENT LIABILITIES				
Short-term borrowings (Notes 19 and 34)	\$ 185,737	5	\$ -	-
Financial liabilities at fair value through profit or loss - current (Notes 4, 7 and 20)	45	-	19,500	-
Contract liabilities - current (Notes 4 and 24)	2,591	-	907	-
Trade payables	80,204	2	108,530	3
Trade payables to related parties (Note 33)	8,775	-	22,429	1
Other payables (Note 21)	126,034	4	95,794	3
Other payables to related parties (Note 33)	220	-	10,862	-
Current tax liabilities (Notes 4 and 26)	16,826	1	18,266	-
Lease liabilities - current (Notes 4 and 15)	5,963	-	4,760	-
Current portion of long-term borrowings (Notes 19, 20 and 34)	51,938	1	508,446	14
Other current liabilities (Notes 21 and 33)	<u>416</u>	<u>-</u>	<u>751</u>	<u>-</u>
Total current liabilities	<u>478,749</u>	<u>13</u>	<u>790,245</u>	<u>21</u>
NON-CURRENT LIABILITIES				
Bonds payable (Notes 4 and 20)	-	-	-	-
Long-term borrowings (Notes 19 and 34)	15,852	1	24,800	1
Deferred tax liabilities (Notes 4 and 26)	42,875	1	38,743	1
Lease liabilities - non-current (Notes 4 and 15)	2,119	-	5,084	-
Net defined benefit liabilities - non-current (Notes 4 and 22)	<u>673</u>	<u>-</u>	<u>669</u>	<u>-</u>
Total non-current liabilities	<u>61,519</u>	<u>2</u>	<u>69,296</u>	<u>2</u>
Total liabilities	<u>540,268</u>	<u>15</u>	<u>859,541</u>	<u>23</u>
EQUITY ATTRIBUTABLE TO OWNERS OF THE COMPANY (Notes 4 and 23)				
Share capital				
Ordinary shares	<u>640,340</u>	<u>18</u>	<u>640,340</u>	<u>18</u>
Capital surplus	<u>782,370</u>	<u>21</u>	<u>781,838</u>	<u>21</u>
Retained earnings				
Legal reserve	245,658	6	231,923	6
Special reserve	512,043	14	422,189	12
Unappropriated earnings	<u>652,137</u>	<u>18</u>	<u>690,096</u>	<u>19</u>
Total retained earnings	<u>1,409,838</u>	<u>38</u>	<u>1,344,208</u>	<u>37</u>
Other equity	<u>(317,313)</u>	<u>(9)</u>	<u>(512,043)</u>	<u>(14)</u>
Total equity attributable to owners of the Company	2,515,235	68	2,254,343	62
NON-CONTROLLING INTERESTS (Note 23)	<u>615,071</u>	<u>17</u>	<u>559,851</u>	<u>15</u>
Total equity	<u>3,130,306</u>	<u>85</u>	<u>2,814,194</u>	<u>77</u>
TOTAL	<u>\$ 3,670,574</u>	<u>100</u>	<u>\$ 3,673,735</u>	<u>100</u>

The accompanying notes are an integral part of the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2024		2023	
	Amount	%	Amount	%
OPERATING REVENUE (Notes 4, 24 and 33)				
Sales	\$ 2,458,636	100	\$ 2,826,587	100
OPERATING COSTS (Notes 11, 25 and 33)				
Cost of goods sold	<u>(1,790,045)</u>	<u>(73)</u>	<u>(2,238,608)</u>	<u>(79)</u>
GROSS PROFIT	<u>668,591</u>	<u>27</u>	<u>587,979</u>	<u>21</u>
OPERATING EXPENSES (Notes 25 and 33)				
Selling and marketing expenses	(233,401)	(10)	(160,186)	(6)
General and administrative expenses	(267,739)	(11)	(236,166)	(8)
Research and development expenses	(3,739)	-	(3,731)	-
Expected credit (loss) gain (Notes 10 and 33)	<u>(7,835)</u>	<u>-</u>	<u>1,999</u>	<u>-</u>
Total operating expenses	<u>(512,714)</u>	<u>(21)</u>	<u>(398,084)</u>	<u>(14)</u>
PROFIT FROM OPERATIONS	<u>155,877</u>	<u>6</u>	<u>189,895</u>	<u>7</u>
NON-OPERATING INCOME AND EXPENSES (Notes 25 and 33)				
Interest income	35,234	1	30,417	1
Other income	14,560	1	4,944	-
Other gains and losses	50,370	2	31,012	1
Finance costs	(6,083)	-	(3,983)	-
Share of profit of associates (Note 13)	<u>2,812</u>	<u>-</u>	<u>5,345</u>	<u>-</u>
Total non-operating income and expenses	<u>96,893</u>	<u>4</u>	<u>67,735</u>	<u>2</u>
PROFIT BEFORE INCOME TAX	252,770	10	257,630	9
INCOME TAX EXPENSE (Notes 4 and 26)	<u>(78,280)</u>	<u>(3)</u>	<u>(68,321)</u>	<u>(2)</u>
NET PROFIT FOR THE YEAR	<u>174,490</u>	<u>7</u>	<u>189,309</u>	<u>7</u>
OTHER COMPREHENSIVE INCOME (LOSS) (Notes 4, 23 and 26)				
Items that will not be reclassified subsequently to profit or loss:				
Remeasurement of defined benefit plans (Note 22)	76	-	(71)	-
Unrealized gain on investments in equity instruments at fair value through other comprehensive income	287	-	-	-

(Continued)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In Thousands of New Taiwan Dollars, Except Earnings Per Share)

	2024		2023	
	Amount	%	Amount	%
Exchange differences on translation to the presentation currency	\$ 267,622	11	\$ (113,042)	(4)
Income tax related to items that will not be reclassified subsequently to profit or loss	<u>(17)</u>	<u>-</u>	<u>16</u>	<u>-</u>
	<u>267,968</u>	<u>11</u>	<u>(113,097)</u>	<u>(4)</u>
Items that may be reclassified subsequently to profit or loss:				
Exchange differences on translation of the financial statements of foreign operations	(24,760)	(1)	4,331	-
Income tax relating to items that may be reclassified subsequently to profit or loss	<u>5,252</u>	<u>-</u>	<u>(712)</u>	<u>-</u>
	<u>(19,508)</u>	<u>(1)</u>	<u>3,619</u>	<u>-</u>
Other comprehensive income (loss) for the year, net of income tax	<u>248,460</u>	<u>10</u>	<u>(109,478)</u>	<u>(4)</u>
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	<u>\$ 422,950</u>	<u>17</u>	<u>\$ 79,831</u>	<u>3</u>
NET PROFIT ATTRIBUTABLE TO:				
Owners of the Company	\$ 128,588	5	\$ 139,361	5
Non-controlling interests	<u>45,902</u>	<u>2</u>	<u>49,948</u>	<u>2</u>
	<u>\$ 174,490</u>	<u>7</u>	<u>\$ 189,309</u>	<u>7</u>
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO:				
Owners of the Company	\$ 323,377	13	\$ 49,452	2
Non-controlling interests	<u>99,573</u>	<u>4</u>	<u>30,379</u>	<u>1</u>
	<u>\$ 422,950</u>	<u>17</u>	<u>\$ 79,831</u>	<u>3</u>
EARNINGS PER SHARE (Note 27)				
From continuing operations				
Basic	<u>\$ 2.01</u>		<u>\$ 2.18</u>	
Diluted	<u>\$ 1.94</u>		<u>\$ 2.13</u>	

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

**CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023
(In Thousands of New Taiwan Dollars)**

	Equity Attributable to Owners of the Company										Total Equity
	Share Capital		Retained Earnings				Other Equity			Non-controlling Interests	
	Number of Shares (In Thousands)	Amount	Capital Surplus	Legal Reserve	Special Reserve	Unappropriated Earnings	Exchange Differences on Translation of the Financial Statements of Foreign Operations	Unrealized Gain on Financial Assets at Fair Value Through Other Comprehensive Income	Total		
BALANCE AT JANUARY 1, 2023	64,034	\$ 640,340	\$ 781,838	\$ 195,237	\$ 527,952	\$ 643,755	\$ (422,189)	\$ -	\$ 2,366,933	\$ 496,276	\$ 2,863,209
Appropriation of 2022 earnings (Note 23)	-	-	-	36,686	-	(36,686)	-	-	-	-	-
Legal reserve	-	-	-	-	-	105,763	-	-	-	-	-
Special reserve	-	-	-	-	(105,763)	(160,085)	-	-	(160,085)	-	(160,085)
Cash dividends distributed by the Company	-	-	-	-	-	-	-	-	-	-	-
Cash dividends distributed by subsidiaries	-	-	-	-	-	-	-	-	-	(20,360)	(20,360)
Net profit for the year ended December 31, 2023	-	-	-	-	-	139,361	-	-	139,361	49,948	189,309
Other comprehensive loss for the year ended December 31, 2023, net of income tax (Note 23)	-	-	-	-	-	(65)	(89,854)	-	(89,909)	(19,569)	(109,478)
Total comprehensive income (loss) for the year ended December 31, 2023	-	-	-	-	-	139,306	(89,854)	-	49,452	30,379	79,831
Increases in non-controlling interests (Note 23)	-	-	-	-	-	-	-	-	-	32,490	32,490
Acquisition of additional non-controlling interests in subsidiaries (Notes 23 and 28)	-	-	-	-	-	-	-	-	-	19,109	19,109
Change in percentage of ownership interests in subsidiaries (Notes 23 and 29)	-	-	-	-	-	(1,957)	(512,043)	-	(1,957)	1,957	-
BALANCE AT DECEMBER 31, 2023	64,034	640,340	781,838	231,923	422,189	690,096	(1,957)	-	2,254,343	559,851	2,814,194
Appropriation of 2023 earnings (Note 23)	-	-	-	13,735	-	(13,735)	-	-	-	-	-
Legal reserve	-	-	-	-	-	89,854	-	-	-	-	-
Special reserve	-	-	-	-	89,854	(89,854)	-	-	(64,034)	-	(64,034)
Cash dividends distributed by the Company	-	-	-	-	-	(64,034)	-	-	-	-	-
Cash dividends distributed by subsidiaries	-	-	-	-	-	-	-	-	-	(42,804)	(42,804)
Net profit for the year ended December 31, 2024	-	-	-	-	-	128,588	-	-	128,588	45,902	174,490
Other comprehensive income for the year ended December 31, 2024, net of income tax (Note 23)	-	-	-	-	-	59	194,443	287	194,789	53,671	248,460
Total comprehensive income for the year ended December 31, 2024	-	-	-	-	-	128,647	194,443	287	323,377	99,573	422,920
Changes in percentage of ownership interests in subsidiaries (Notes 23 and 29)	-	-	-	-	-	1,017	-	-	1,549	(1,549)	-
BALANCE AT DECEMBER 31, 2024	64,034	640,340	782,370	245,658	512,043	652,137	(317,600)	287	2,515,235	615,071	3,130,306

The accompanying notes are an integral part of the consolidated financial statements.

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023 (In Thousands of New Taiwan Dollars)

	2024	2023
CASH FLOWS FROM OPERATING ACTIVITIES		
Income before income tax	\$ 252,770	\$ 257,630
Adjustments for:		
Depreciation expense	52,332	48,410
Amortization expense	1,647	737
Expected credit loss recognized (reversed) on trade receivables	7,835	(1,999)
Net (gain) loss on fair value changes of financial assets/liabilities at fair value through profit or loss	(5,775)	7,808
Finance costs	6,083	3,983
Interest income	(35,234)	(30,417)
Share of profit of associates	(2,812)	(5,345)
(Gain) loss on disposal of property, plant and equipment	(1,204)	418
Gain from lease modification	(39)	-
Gain on redemption of bonds payable	(5,771)	-
Unrealized loss (gain) on foreign exchange	21,795	(14,136)
Impairment loss recognized on goodwill	796	-
Changes in operating assets and liabilities		
Financial assets mandatorily classified as at fair value through profit or loss	663	374
Trade receivables	(155,496)	231,330
Trade receivables from related parties	9,769	17,663
Other receivables	(568)	257
Inventories	(28,808)	537,702
Prepayments	(190)	(1,625)
Contract liabilities	1,534	(4,970)
Trade payables	(35,264)	33,604
Trade payables to related parties	(14,560)	14,372
Other payables	22,462	(32,610)
Other payables to related parties	(69)	12
Other current liabilities	(426)	(16)
Net defined benefit liabilities	66	615
Cash generated from operations	91,536	1,063,797
Interest received	35,315	29,160
Interest paid	(5,715)	(3,168)
Income tax paid	(66,950)	(130,546)
Net cash generated from operating activities	54,186	959,243
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchase of financial assets at amortized cost	(161,772)	(70,194)
Proceeds from sale of financial assets at amortized cost	68,139	34,126
Purchase of financial assets at fair value through profit or loss	(10,128)	(40,971)
Proceeds from sale of financial assets at fair value through profit or loss	10,213	-
		(Continued)

ALL COSMOS BIO-TECH HOLDING CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED DECEMBER 31, 2024 AND 2023

(In Thousands of New Taiwan Dollars)

	2024	2023
Purchase of financial assets at fair value through other comprehensive income	\$ (4,824)	\$ -
Acquisition of subsidiaries	-	29,638
Payments for property, plant and equipment	(139,699)	(155,472)
Proceeds from disposal of property, plant and equipment	1,505	328
Increase in refundable deposits	(1,488)	-
Decrease in refundable deposits	-	3,405
Decrease in other receivables from related parties	7,458	4,112
Payments for intangible assets	(2,549)	(673)
Increase in prepayment for equipment	-	(7,278)
Decrease in prepayment for equipment	<u>4,689</u>	<u>-</u>
Net cash used in investing activities	<u>(228,456)</u>	<u>(202,979)</u>
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from short-term borrowings	187,548	-
Repayments of short-term borrowings	(24,827)	(386,482)
Repayments of bonds	(468,532)	-
Repayments of long-term borrowings	(10,349)	(9,635)
Proceeds from guarantee deposits received	36	286
Increase in other payables to related parties	267	-
Repayment of the principal portion of lease liabilities	(5,798)	(6,096)
Dividends paid to owners of the Company	(64,034)	(160,085)
Changes in non-controlling interests	-	32,490
Dividends paid to non-controlling interests	<u>(42,804)</u>	<u>(20,360)</u>
Net cash (used in) generated from financing activities	<u>(428,493)</u>	<u>(549,882)</u>
EFFECTS OF EXCHANGE RATE CHANGES ON THE BALANCE OF CASH HELD IN FOREIGN CURRENCIES		
	<u>77,828</u>	<u>(89,029)</u>
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(524,935)	117,353
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE YEAR	<u>1,458,863</u>	<u>1,341,510</u>
CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR	<u>\$ 933,928</u>	<u>\$ 1,458,863</u>

The accompanying notes are an integral part of the consolidated financial statements.

(Concluded)

Attachment VI**All Cosmos Bio-Tech Holding Corporation****Year 2024 Earnings Distribution Proposal**

Unit:NT\$

Items		Amount
Beginning Balance of Undistributed Earnings		522,473,143
Add : Net Profit for the Period	128,588,414	
Remeasurement amounts of defined benefit plans are recognized in retained earnings	59,029	
Adjustment of retained earnings due to investment using equity method	1,017,036	
The amount of Net profit for the Period plus other items included in current year's undistributed surplus		129,664,479
Less : 10% Legal Reserve		(12,966,448)
Plus : Reverse the Special Surplus Reserve According to Law		194,729,980
Available for Distribution Surplus *		833,901,154
Distributable Items		
Stock Dividends to shareholders NT\$ 0.5 per share (0.05 shares per share calculated based on the share capital on 2024/12/31)		(32,017,000)
Cash Dividends to shareholders (NT\$ 0.5 per share) 64,034,001 shares		(32,017,000)
Closing Balance of Undistributed Earnings		769,867,154

Note :

1. The distribution of cash dividends out of surplus is in accordance with 125A of the Company's Articles of Association, which authorizes the Board of Directors to make a resolution and submit it to the shareholders' meeting.
2. The Cash Dividend is NT\$0.5 per share, and a stock dividend is NT\$0.5 per share, total dividend amount is NT\$1 per share. The distributed amount will be in round numbers, the remainder will be treated as other income.
3. If the Company subsequently buys back the shares of the Company, transfers, converts and cancels the treasury shares, or according to the issue and conversion rules to convert the Company Bonds, which affects the amount of shares outstanding, the share allotment and the changes of the dividend yields, will raise request to shareholders' meeting to authorize the Chairman to handle the matter.

Attachment VII

Comparison Table of Original and Amended “Articles of Association

Article Number	Current Articles	Amended Articles	Explanations
48B	<p>For so long as the Shares are registered in the Emerging Market or listed on the Taipei Exchange or TSE, the Company shall make public announcements with regard to notice of general meeting, proxy form, and summary information and details about issues for recognition, discussion, election or dismissal of Directors or supervisors (if any) at least thirty (30) days prior to any annual general meeting or at least fifteen (15) days prior to any extraordinary general meeting.</p> <p>If the Company allows the Shareholders to exercise the votes and cast the votes in writing or by way of electronic transmission in accordance with Article 67, the Company shall also send to the Shareholders the information and documents as described in the preceding paragraph, together with the voting right exercise forms.</p>	<p>For so long as the Shares are registered in the Emerging Market or listed on the Taipei Exchange or TSE, the Company shall make public announcements with regard to notice of general meeting, proxy form, and summary information and details about issues for recognition, discussion, election or dismissal of Directors or supervisors at least thirty (30) days prior to any annual general meeting or at least fifteen (15) days prior to any extraordinary general meeting.</p> <p>If the Company allows the Shareholders to exercise the votes and cast the votes in writing or by way of electronic transmission in accordance with Article 67, the Company shall also send to the Shareholders the information and documents as described in the preceding paragraph, together with the voting right exercise forms.</p>	<p>This paragraph is revised in accordance with the Checklist for Protecting Shareholders of Foreign Issuers amended on May 2, 2024.</p>
49	<p>For so long as the Shares are registered in the Emerging Market or listed on the Taipei Exchange or TSE, the Board shall prepare a manual setting out the agenda of a general meeting (including all the subjects and matters to be resolved at the meeting) and shall make public announcement(s) in a manner</p>	<p>For so long as the Shares are registered in the Emerging Market or listed on the Taipei Exchange or TSE, the Board shall prepare a manual setting out the agenda of a general meeting (including all the subjects and matters to be resolved at the meeting) and shall make public announcement(s) in a manner</p>	<p>This paragraph is revised in accordance with the Checklist for Protecting Shareholders of Foreign Issuers amended on May 2, 2024.</p>

Article Number	Current Articles	Amended Articles	Explanations
49	<p>permitted by the Applicable Listing Rules to disclose the contents of such manual together with other information related to the said meeting at least twenty-one (21) days prior to the date of annual general meetings and at least fifteen (15) days prior to the date of extraordinary general meetings. Such manual shall be distributed to all Shareholders attending the general meeting in person, by proxy or by corporate representative(s) (where the Shareholder is a corporation) at the general meeting. Where the Company's paid-in capital has reached NT\$ <u>10 billion</u> or more on the last day of the most recent fiscal year, or the aggregate shareholding of foreign Shareholders and PRC shareholders has reached 30% or more on the book closure day of the annual general meeting in the most recent fiscal year, the Company shall complete the transmission of the aforementioned electronic documents thirty (30) days prior to the date of annual general meetings.</p>	<p>permitted by the Applicable Listing Rules to disclose the contents of such manual together with other information related to the said meeting at least twenty-one (21) days prior to the date of annual general meetings and at least fifteen (15) days prior to the date of extraordinary general meetings. Such manual shall be distributed to all Shareholders attending the general meeting in person, by proxy or by corporate representative(s) (where the Shareholder is a corporation) at the general meeting. Where the Company's paid-in capital has reached <u>NT\$ 2 billion</u> or more on the last day of the most recent fiscal year, or the aggregate shareholding of foreign Shareholders and PRC shareholders has reached 30% or more on the book closure day of the annual general meeting in the most recent fiscal year, the Company shall complete the transmission of the aforementioned electronic documents thirty (30) days prior to the date of annual general meetings.</p>	

Attachment VIII

All Cosmos Bio-Tech Holding Corporation

List of Director Candidates

Title	Name	Education	Experience	Shares
Chairman	Peng Shih Hao	Ph.D., Institute of Wood Science and Technology, University of Putra, Malaysia Master of Business Administration, Honolulu University, Hawaii	CEO & Director, ACI Director, SSHF Director, KLSSB Director, SESB Director, GK Bio Director, PT Biotek Director, EEMSB Director, CNSB Chairman, All Cosmos Investment Ltd.	245,000
Director	Peng Chia Lin	Shih Hsin College of Journalism and Communication	Director of Clinical Research, Quintiles Director, GK Bio Director, EEMSB Vice President, ACBT Taiwan Director, Maxtrench Corp.	45,000
Director	Peng Yi Fen	Queensborough Community College-Associate in Science	Senior Manager, ACI Director, ACI Director, CNSB Director, Asia Win Development Ltd.	11,000
Director	Lim Tau Boon	Diploma in Mechanical Engineering from Singapore Polytechnic Diploma in Industrial Management from Singapore Polytechnic	Director, SSHF Director, KLSSB Director, AESB COO, ACI Vietnam Regional Director , Intraco Ltd. Regional Manager in Dalian and Shanghai, Intraco Ltd International Operation Manager, Intraco Ltd	-
Director	Lo Tzu-Wu	Institute of Law, National Chung Hsing University	Weiyang Law Firm Lawyer Supervisor, Sea way Technology Co., Ltd. Person in charge, Sea Way Energy Co., Ltd Person in charge, Hui Yang Energy Co., Ltd Supervisor, Hong Sheng Co., Ltd.	-
Independent Director	Yang Yung-Cheng	Institute of Law, National Chung Hsing University Certified Accountant of higher examination Accountant,	Person in charge, Moores Rowland CPAs Supervisor, Yungchan Construction Co., Ltd Supervisor, Dan Jie Construction Co., Ltd Supervisor, Mega Bank Independent director, Timing Pharmaceutical Co., Ltd	-

Title	Name	Education	Experience	Shares
Independent Director	Lee Wen-Chuan	Bachelor of Plant Pathology, National Chung Hsing University Ph. D, Post-Doctoral Research, Department of Life Science, National Tsing Hua University Post Doctoral Research, UCLA	Principle, Agricultural Technology Research Institute Principle, Reboot Agricultural Technology., Ltd Consultant, Agricultural Bank of Taiwan Deputy Chairman, Taiwan Formosa Organic Association Consultant, Agricultural Bank of Taiwan Consultant, Hsin Chu County Local Industry Consultant, Tze Chiang Foundation Committee Member, Harmony Organic Agriculture Foundation Committee Member, Miaoli Management Office, Irrigation Agency, Ministry of Agriculture	-
Independent Director	Juan, Chiung-Hua	Master in Accounting, National Taiwan University Certified Accountant of higher examination Certified Valuation Analyst Qualified Lecture	CPA, Smart CPA firm Committee, CPA Association Independent Director, Gene Touch Corp., Independent Director, TTFB Restaurant Group	-
Independent Director	Ho, Chia-Fang	Ph.D. in Legal Research, Osaka University Master in Legal Research, Osaka University Master in Law, Department of Law, National Taipei University	Associate Professor, Department of Law, SooChow University Exchange Committee, SooChow University Supervisor, Taiwan Society of Health Law Supervisor, Taipei Dispute Resolution Study Society Consultant, Taiwan Bar Association Director, Taiwan Private International Law Association	-

Attachment IV

Proposal of Release the Prohibition on Directors from Participation in Competitive Business

Title	Name	Positions in other companies
Chairman	Peng Shih Hao	Director, All Cosmos Industries Sdn. Bhd. Director, Sabah Softwoods Hybrid Fertiliser Sdn. Bhd. Director, Sawit Ecoshield Sdn. Bhd. Director, GK Bio International Sdn. Bhd. Director, PT All Cosmos Biotek Director, Cosmos Nutriscience Sdn. Bhd. Director, Eastern Eckare Malaysia Sdn. Bhd.
Director	Peng Chia Lin	Director, GK Bio International Sdn. Bhd. Director, Eastern Eckare Malaysia Sdn. Bhd.
Director	Peng Yi Fen	Director, All Cosmos Industries Sdn. Bhd. Director, Cosmos Nutriscience Sdn. Bhd.
Director	Lim Tau Boon	Director, Sabah Softwoods Hybrid Fertiliser Sdn. Bhd. Director, Kinabalu Life Sciences Sdn. Bhd.
Director	Lo Tzu-Wu	Supervisor, Sea way Technology Co., Ltd. Person in charge, Sea Way Energy Co., Ltd Person in charge, Hui Yang Energy Co., Ltd Supervisor, Hong Sheng Co., Ltd.
Independent Director	Yang Yung-Cheng	Supervisor, Yungchan Construction Co., Ltd Supervisor, Dan Jie Construction Co., Ltd Supervisor, Mega Bank Independent director, Timing Pharmaceutical Co., Ltd
Independent Director	Lee Wen-Chuan	Principle, Reboot Agricultural Technology., Ltd Deputy Chairman, Taiwan Formosa Organic Association
Independent Director	Juan Chiung-Hua	Independent Director, Gene Touch Corp. Independent Director, TTFB Restaurant Group